Home » FDA Approves Peptide Developed in the Hruby Lab

FDA Approves Peptide Developed in the Hruby Lab

Pictured (l-r): Chris Heward, Mac Hadley, Victor Hruby, and Tomi Sawyer (circa 1980)

The FDA has approved afamelanotide (Scenesse) from Clinuvel Ltd, Melbourne, Australia, as a treatment for the extreme light sensitivity in patients with erythropoietic protoporphyria (EPP). This caps research done at the University of Arizona over twenty years ago. Congratulations to peptide chemists Tomi Sawyer and Victor Hruby, and the late biologist Mac Hadley for creating this molecule, and for the Skin Cancer Prevention Program Project Grant for funding its preclinical and early clinical development.

 

 

 

 

 

FDA approves first treatment to increase pain-free light exposure in patients with a rare disorderTuesday, October 8, 2019Home